5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis

A compound of the formula:

• ##STR19## wherein:
• A is CH.sub.2 ;
• B, D and E are CH;
• Y is
• (a) phenyl, optionally substituted with 1-3 substituents independently selected from R.sup.4 ;
• (b) naphthyl, optionally substituted with 1-3 substituents independently selected from R.sup.4 ;
• (c) C.sub.3 -C.sub.8 cycloalkyl, optionally substituted with 1-2 substituents independently selected from R.sub.4 ;
• (d) C.sub.3 -C.sub.8 cycloalkenyl, optionally substituted with 1-2 substituents independently selected from R.sup.4 ;
• (e) a five membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NR.sup.2 - and -S(O).sub.n -, optionally substituted with 1-3 substituents independently selected from R.sup.4 ;
• (f) a six membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NR.sup.2 - and -S(O).sub.n - optionally substituted with 1-3 substituents independently selected from R.sup.4 ;
• or
• (g) a bicyclic ring system consisting of a five or six membered heterocyclic ring fused to a phenyl ring, said heterocyclic ring containing up to two heteroatoms selected from the group consisting of -O-, -NR.sup.2 -, NR.sup.2 - and -S(O).sub.n -, optionally substituted with 1-3 substituents independently selected from R.sup.4.
• Z.sup.1 is
• (a) -O(CH.sub.2).sub.P CR.sup.5 R.sup.6 -;
• (b) -O(CH.sub.2).sub.P W(CH.sub.2).sub.q ;
• or
• (c) -OCHR.sup.2 CHR.sup.3 -;
• G is -NR.sup.7 R.sup.8 ;
• W is
• (a) -CH.sub.2 -;
• (b) -CH.dbd.CH-;
• (c) -O-;
• (d) -NR.sup.2 -;
• (e) -S(O).sub.n -;
• ##STR20## (g) -CR.sup.2 (OH)-;
• (h) -CONR.sup.2 -;
• (i) -NR.sup.2 CO-;
• ##STR21## or (k) -C.dbd.C-;
• R.sup.2 and R.sup.3 are independently
• (a) hydrogen;
• or
• (b) C.sub.1 -C.sub.4 alkyl;
• R.sup.4 is
• (a) hydrogen;
• (b) halogen;
• (c) C.sub.1 -C.sub.6 alkyl;
• (d) C.sub.1 -C.sub.4, alkoxy;
• (e) C.sub.1 -C.sub.4 acyloxy;
• (f) C.sub.1 -C.sub.4 alkylthio;
• (g) C.sub.1 -C.sub.4 alkylsulfinyl;
• (h) C.sub.1 -C.sub.4 alkylsulfonyl;
• (i) hydroxy (C.sub.1 -C.sub.4)alkyl;
• (j) aryl (C.sub.1 -C.sub.4)alkyl;
• (k) -CO.sub.2 H;
• (I) -CN;
• (m) -CONHOR;
• (n) -SO.sub.2 NHR;
• (o) -NH.sub.2 ;
• (p) C.sub.1 -C.sub.4 alkylamino;
• (q) C.sub.1 -C.sub.4 dialkylamino;
• (r) -NHSO.sub.2 R;
• (s) -NO.sub.2 ;
• (t) -aryl;
• or
• (u) -OH.
• R.sup.5 and R.sup.6 are independently C.sub.1 -C.sub.8 alkyl or together form a C.sub.3 -C.sub.10 carbocyclic ring;
• R.sup.7 and R.sup.8 in ring form may optionally be substituted with up to three substituents independently selected from C.sub.1 -C.sub.6 alkyl, halogen, alkoxy, hydroxy and carboxy;
• a ring formed by R.sup.7 and R.sup.8 may be optionally fused to a phenyl ring;
• e is 1 or 2;
• p is 0, 1, 2 or 3;
• q is 0, 1, 2 or 3;
• and optical and geometric isomers thereof;
• and nontoxic pharmacologically acceptable acid addition salts, N-oxides, esters, and quaternary ammonium salts thereof.